Mark James Litton, President and CEO at Athira Pharma, Inc. (ATHA), sold 2,586 shares at $6.88 ($18K) on 2026-01-02, disclosed to the SEC on 2026-01-05.
Open-market sale of $18k ATHA by President and CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| ATHA | SELL | 2025-01-03 | $14K | — | Filing → |
| ATHA | SELL | 2024-09-05 | $3K | — | Filing → |
| ATHA | SELL | 2024-02-16 | $14K | — | Filing → |